Key Takeaways
- Health Canada has five high-priority oncology submissions under active review expected to reach decision by Q4 2026.
- The pipeline includes checkpoint inhibitors, antibody-drug conjugates (ADCs), and a bispecific T-cell engager representing three distinct mechanisms of action.
- Combined addressable Canadian patient populations for the five drugs exceed 14,000 patients annually.
- Canadian revenues across all five drugs are estimated at $280-340 million annually at peak penetration.
Health Canada’s oncology review queue for the second half of 2026 includes some of the most anticipated cancer drug submissions in the agency’s recent history. From checkpoint inhibitors seeking expanded indications to first-in-class antibody-drug conjugates targeting tumour-specific antigens, the five drugs most likely to receive Canadian authorization before year-end represent a meaningful expansion of the country’s oncology formulary and a significant commercial opportunity for the companies behind them.
The Five Drugs to Watch
1. Tarlatamab (Imdelltra) Amgen’s DLL3-targeted bispecific T-cell engager for small cell lung cancer, a disease with notoriously limited treatment options in the relapsed/refractory setting. The drug received FDA Accelerated Approval in May 2024 based on a 40% objective response rate in heavily pretreated patients. Health Canada’s review is expected to complete in Q3 2026. The Canadian SCLC population eligible for tarlatamab is estimated at 1,200-1,500 patients annually.
2. Datopotamab deruxtecan (Dato-DXd) AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC for hormone receptor-positive, HER2-negative breast cancer the most common breast cancer subtype in Canada. The TROPION-Breast01 trial demonstrated superior progression-free survival versus chemotherapy in a pre-treated population. With approximately 6,400 Canadian women diagnosed with HR+/HER2- metastatic breast cancer annually, this represents the largest addressable population in the H2 2026 oncology pipeline.
| Drug | Mechanism | Indication | Company | Expected HC Decision | Canadian Patients/yr |
|---|---|---|---|---|---|
| Tarlatamab (Imdelltra) | Bispecific T-cell engager | Relapsed/refractory SCLC | Amgen | Q3 2026 | ~1,400 |
| Dato-DXd (Datroway) | ADC (TROP2) | HR+/HER2- metastatic breast cancer | AstraZeneca/Daiichi Sankyo | Q3 2026 | ~6,400 |
| Ivonescimab | PD-1/VEGF bispecific | Non-small cell lung cancer (1L) | Akeso/Summit Therapeutics | Q4 2026 | ~2,800 |
| Patritumab deruxtecan (HER3-DXd) | ADC (HER3) | EGFR-mutated NSCLC post-osimertinib | Daiichi Sankyo/AstraZeneca | Q4 2026 | ~1,100 |
| Nivolumab + relatlimab (Opdualag) | PD-1 + LAG-3 checkpoint | Unresectable/metastatic melanoma | Bristol-Myers Squibb | Q3 2026 | ~2,200 |
The ADC Moment in Canadian Oncology
Two of the five drugs Dato-DXd and patritumab deruxtecan are antibody-drug conjugates from Daiichi Sankyo’s ADC platform, partnered with AstraZeneca in a deal valued at up to US$6.9 billion. The success of this platform in late-line and second-line settings is now pushing into first- and second-line indications, dramatically expanding the addressable population and the commercial stakes. For Canadian oncologists and patients, these two drugs represent meaningful options in cancers where existing therapies have left significant unmet need.
Investor Angle: Canadian Biotech Beneficiaries
None of the five drugs in Health Canada’s H2 2026 oncology pipeline are from Canadian companies. But Canadian investors should be watching the indirect beneficiaries. Companies like Champions Oncology and Canadian CROs that run companion diagnostic studies benefit from the clinical infrastructure requirements of ADC and bispecific programs. More directly, Zymeworks (ZYME), the Vancouver-based bispecific and ADC platform company, is developing its own ADC candidates that would flow through a similar Health Canada review process in future years and the establishment of a robust ADC precedent in Canada’s regulatory framework benefits Zymeworks’ long-term commercialization planning.
The Bottom Line
Health Canada’s H2 2026 oncology pipeline includes genuinely impactful drugs addressing significant Canadian patient populations in lung cancer, breast cancer, and melanoma. The approval of these five drugs before year-end would represent one of the strongest six-month periods for Canadian oncology access in the agency’s history, and the commercial revenues generated would materially benefit the pharma companies involved while creating a stronger evidence base for the ADC and bispecific mechanisms that are reshaping the global oncology landscape.